Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (Blossom)
A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Macular Edema Secondary to Branch Retinal Vein Occlusion, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bandung, Indonesia , Beijing, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hanoi, Vietnam , Harbin, China , Ho Chi Minh City, Vietnam , Hong Kong, Hong Kong and 15 more locations